|
Marknaden stängd -
Andra börsplatser
|
Efter stängning 02.00.00 | |||
| 119,52 USD | −1,05 % |
|
109,99 | −7,97 % |
| 06-08 | Gilead och Mercks HIV-kombination uppnår primära effektmått i två fas 3-studier | MT |
| 06-08 | Merck och Gilead avbryter fas 3-studie med Trodelvy och Keytruda mot lungcancer | MT |
Försäljning 2025 per affärssegment
Försäljning 2025 efter Geografi
Historisk fördelning av intäkter per affärssegment
Operating Income: Fördelning efter verksamhetssegment
| Skatteperiod: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical | 42,75 md | 52 md | 53,58 md | 57,4 md | 58,14 md | |||||
D&A | 6 mn | 5 mn | 5 mn | 5 mn | 5 mn | |||||
Operating Income | 30,98 md | 36,85 md | 38,88 md | 44,53 md | 45,75 md | |||||
Veterinary Drugs | ||||||||||
Animal Health | 5,57 md | 5,55 md | 5,62 md | 5,88 md | 6,35 md | |||||
D&A | 158 mn | 177 mn | 198 mn | 256 mn | 282 mn | |||||
Operating Income | 1,95 md | 1,96 md | 1,74 md | 1,94 md | 2,13 md | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Unallocated Other Revenues | 382 mn | 1,73 md | 907 mn | 891 mn | 515 mn | |||||
Operating Income | 156 mn | 1,16 md | 474 mn | 492 mn | 251 mn | |||||
Other | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Operating Income | −1,41 md | −1,64 md | −1,62 md | −1,84 md | −2,76 md | |||||
Operating Income | −1,64 md | −2,08 md | −2,04 md | −2,4 md | −2,79 md | |||||
Operating Income | −11,69 md | −13,01 md | −30,01 md | −17,35 md | −14,99 md |
Historik över geografisk fördelning av omsättning
| Skatteperiod: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 22,42 md | 27,21 md | 28,48 md | 32,28 md | 36,51 md | |||||
Total Assets | 11,76 md | 12,89 md | 13,92 md | 14,72 md | 15,02 md | |||||
Europe, Middle East and Africa | 13,34 md | 14,49 md | 13,25 md | 14,04 md | 14,58 md | |||||
Total Assets | 6,08 md | 6,99 md | 7,56 md | 7,55 md | 8,86 md | |||||
Latin America | 2,21 md | 2,58 md | 3,09 md | 3,46 md | 3,41 md | |||||
Total Assets | 199 mn | 225 mn | 222 mn | 133 mn | 128 mn | |||||
Asia Pacific (other than Japan and China) | 2,41 md | 3,61 md | 3,22 md | 3,06 md | 2,98 md | |||||
Total Assets | 857 mn | 966 mn | 1,02 md | 982 mn | 898 mn | |||||
Other | 1,22 md | 2,57 md | 2,1 md | 2,56 md | 2,88 md | |||||
Total Assets | 4 mn | 5 mn | 4 mn | 47 mn | 51 mn | |||||
Japan | 2,73 md | 3,63 md | 3,16 md | 3,28 md | 2,71 md | |||||
Total Assets | 159 mn | 135 mn | 133 mn | 143 mn | 144 mn | |||||
China | 4,38 md | 5,19 md | 6,8 md | 5,49 md | 1,94 md | |||||
Total Assets | 220 mn | 207 mn | 193 mn | 202 mn | 218 mn | |||||
Asia Pacific | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Börsen
- Aktier
- MRK Aktie
- Finanser Merck & Co., Inc.
- Affärssegment
Välj din utgåva
All finansiell information anpassad till den nationella nivån
MarketScreener is also available in this country: United States.
Switch edition















